

SPEAKER: In those patients who have more advanced disease-- say, cavitation-- the recommendations are to add another agent. And typically that would be using systemically delivered amikacin. Obviously this is-- it's not approved for that use. But that is a strategy that we have implemented. And the belief is that there is a much more serious infection and we need to come in hard with another highly effective drug, amikacin. And so we will typically treat those patients for six to eight weeks of IV amikacin, after which we will then switch them to an inhaled form of amikacin and continue with that four-drug regimen for the duration.